Advances in treatment of achondroplasia and osteoarthritis

Human Molecular Genetics

Volumn 25, Issue R1, 2016, Pages R2-R8

  Klag, Kendra A ^a,b   Horton, William A ^a,b  

^a SHRINERS HOSPITAL FOR CHILDREN   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GREEN FLUORESCENT PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MECLOZINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NATRIURETIC PEPTIDE TYPE C; NEUTRALIZING ANTIBODY; ROSUVASTATIN; SCATTER FACTOR; STAT PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; VIRUS VECTOR; VOSORITIDE;

ACHONDROPLASIA; ADENO ASSOCIATED VIRUS; ARTICULAR CARTILAGE; BACKACHE; BONE GROWTH; BREAST CANCER; CANCER THERAPY; CHONDROCYTE; CHONDRODYSPLASIA; CHONDROGENESIS; CHONDROSARCOMA; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; COUGHING; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; ENCHONDRAL OSSIFICATION; ENDOCYTOSIS; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; EPIPHYSEAL CARTILAGE; EPIPHYSIS PLATE; FAMILIAL HYPERCHOLESTEROLEMIA; FEVER; FIBROBLAST; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE THERAPY; GROWTH RATE; HEADACHE; HEART RATE; HISTOGENESIS; HUMAN; HYPERTROPHY; HYPOTENSION; IMMUNOGENICITY; IN VIVO STUDY; INJECTION SITE REACTION; MACACA FASCICULARIS; MOUSE; NONHUMAN; OBESITY; ORTHOPEDIC SURGERY; OSSIFICATION; OSTEOARTHRITIS; OXIDATIVE STRESS; PHAGE DISPLAY; PHASE 2 CLINICAL TRIAL (TOPIC); PI3K/AKT SIGNALING; POSTNATAL DEVELOPMENT; PRECLINICAL STUDY; REVIEW; SPINAL MUSCULAR ATROPHY; SYNOVIAL FLUID; SYNOVIOCYTE; UTERINE CERVIX CANCER; VIRUS CAPSID; VIRUS SHEDDING; ANIMAL;

ACHONDROPLASIA; ANIMALS; GENETIC THERAPY; HUMANS; MICE; OSTEOARTHRITIS;

EID: 85011737918     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv419     Document Type: Review

References (69)

1. Horton, W.A., Hall, J.G. and Hecht, J.T. (2007) Achondroplasia. Lancet, 370, 162–172.
2. Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J.M., Maroteaux, P., Le Merrer, M. and Munnich, A. (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature, 371, 252–254.
3. Shiang, R., Thompson, L.M., Zhu, Y.Z., Church, D.M., Fielder, T.J., Bocian, M., Winokur, S.T. and Wasmuth, J.J. (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell, 78, 335–342.
4. Sahni, M., Ambrosetti, D.C., Mansukhani, A., Gertner, R., Levy, D. and Basilico, C. (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes. Dev., 13, 1361–1366.
5. Eswarakumar, V.P., Lax, I. and Schlessinger, J. (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev., 16, 139–149.
6. Murakami, S., Balmes, G., McKinney, S., Zhang, Z., Givol, D. and de Crombrugghe, B. (2004) Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes. Dev., 18, 290–305.
7. Zhang, R., Murakami, S., Coustry, F., Wang, Y. and de Crombrugghe, B. (2006) Constitutive activation of MKK6 in chondrocytes of transgenic mice inhibits proliferation and delays endochondral bone formation. Proc. Natl. Acad. Sci. USA, 103, 365–370.
8. Laederich, M.B. and Horton, W.A. (2010) Achondroplasia: pathogenesis and implications for future treatment. Curr. Opin. Pediatr., 22, 516–523.
9. Kronenberg, H.M. (2003) Developmental regulation of the growth plate. Nature, 423, 332–336.
10. Ornitz, D.M. (2005) FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev., 16, 205–213.
11. Horton, W.A. and Degnin, C.R. (2009) FGFs in endochondral skeletal development. Trends Endocrinol. Metab., 20, 341–348.
12. Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J.P. and Radvanyi, F. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet., 23, 18–20.
13. Hartmann, J.T., Haap, M., Kopp, H.G. and Lipp, H.P. (2009) Tyrosine kinase inhibitors—a review on pharmacology, metabolism and side effects. Curr. Drug. Metab., 10, 470–481.
14. Aviezer, D., Golembo, M. and Yayon, A. (2003) Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia—genetic short limbed dwarfism. Curr. Drug. Targets, 4, 353–365.
15. Hall, P.S. and Cameron, D.A. (2009) Current perspective—trastuzumab. Eur. J. Cancer, 45, 12–18.
16. Rauchenberger, R., Borges, E., Thomassen-Wolf, E., Rom, E., Adar, R., Yaniv, Y., Malka, M., Chumakov, I., Kotzer, S., Resnitzky, D. et al. (2003) Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J. Biol. Chem., 278, 38194–38205.
17. Liu, Z., Lavine, K.J., Hung, I.H. and Ornitz, D.M. (2007) FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev. Biol., 302, 80–91.
18. Ohbayashi, N., Shibayama, M., Kurotaki, Y., Imanishi, M., Fujimori, T., Itoh, N. and Takada, S. (2002) FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes. Dev., 16, 870–879.
19. Garcia, S., Dirat, B., Tognacci, T., Rochet, N., Mouska, X., Bonnafous, S., Patouraux, S., Tran, A., Gual, P., Le Marchand-Brustel, Y. et al. (2013) Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci. Transl. Med., 5, 203ra124.
20. Terada, M., Shimizu, A., Sato, N., Miyakaze, S.I., Katayama, H. and Kurokawa-Seo, M. (2001) Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs. Mol. Cell Biol. Res. Commun., 4, 365–373.
21. Wendt, D.J., Dvorak-Ewell, M., Bullens, S., Lorget, F., Bell, S.M., Peng, J., Castillo, S., Aoyagi-Scharber, M., O’Neill, C.A., Krejci, P. et al. (2015) Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J. Pharmacol. Exp. Ther., 353, 132–149.
22. Jin, M., Yu, Y., Qi, H., Xie, Y., Su, N., Wang, X., Tan, Q., Luo, F., Zhu, Y., Wang, Q. et al. (2012) A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Hum. Mol. Genet., 21, 5443–5455.
23. Iwata, T., Chen, L., Li, C., Ovchinnikov, D.A., Behringer, R.R., Francomano, C.A. and Deng, C.X. (2000) A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum. Mol. Genet., 9, 1603–1613.
24. Yamashita, A., Morioka, M., Kishi, H., Kimura, T., Yahara, Y., Okada, M., Fujita, K., Sawai, H., Ikegawa, S. and Tsumaki, N. (2014) Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature, 513, 507–511.
25. Matsushita, M., Kitoh, H., Ohkawara, B., Mishima, K., Kaneko, H., Ito, M., Masuda, A., Ishiguro, N. and Ohno, K. (2013) Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia. PLoS One, 8, e81569.
26. Matsushita, M., Hasegawa, S., Kitoh, H., Mori, K., Ohkawara, B., Yasoda, A., Masuda, A., Ishiguro, N. and Ohno, K. (2015) Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene. Endocrinology, 156, 548–554.
27. Suda, M., Ogawa, Y., Tanaka, K., Tamura, N., Yasoda, A., Takigawa, T., Uehira, M., Nishimoto, H., Itoh, H., Saito, Y. et al. (1998) Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Proc. Natl. Acad. Sci. USA, 95, 2337–2342.
28. Chusho, H., Tamura, N., Ogawa, Y., Yasoda, A., Suda, M., Miyazawa, T., Nakamura, K., Nakao, K., Kurihara, T., Komatsu, Y. et al. (2001) Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc. Natl. Acad. Sci. USA, 98, 4016–4021.
29. Yasoda, A., Komatsu, Y., Chusho, H., Miyazawa, T., Ozasa, A., Miura, M., Kurihara, T., Rogi, T., Tanaka, S., Suda, M. et al. (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat. Med., 10, 80–86.
30. Naski, M.C., Colvin, J.S., Coffin, J.D. and Ornitz, D.M. (1998) Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development, 125, 4977–4988.
31. Kake, T., Kitamura, H., Adachi, Y., Yoshioka, T., Watanabe, T., Matsushita, H., Fujii, T., Kondo, E., Tachibe, T., Kawase, Y. et al. (2009) Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice. Am. J. Physiol. Endocrinol. Metab., 297, E1339–E1348.
32. Yasoda, A., Kitamura, H., Fujii, T., Kondo, E., Murao, N., Miura, M., Kanamoto, N., Komatsu, Y., Arai, H. and Nakao, K. (2009) Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology, 150, 3138–3144.
33. Potter, L.R., Abbey-Hosch, S. and Dickey, D.M. (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev., 27, 47–72.
34. Sellitti, D.F., Koles, N. and Mendonca, M.C. (2011) Regulation of C-type natriuretic peptide expression. Peptides, 32, 1964–1971.
35. Bartels, C.F., Bukulmez, H., Padayatti, P., Rhee, D.K., van Ravenswaaij-Arts, C., Pauli, R.M., Mundlos, S., Chitayat, D., Shih, L.Y., Al-Gazali, L.I. et al. (2004) Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am. J. Hum. Genet., 75, 27–34.
36. Bocciardi, R., Giorda, R., Buttgereit, J., Gimelli, S., Divizia, M.T., Beri, S., Garofalo, S., Tavella, S., Lerone, M., Zuffardi, O. et al. (2007) Overexpression of the C-type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation. Hum. Mutat., 28, 724–731.
37. Yasoda, A., Ogawa, Y., Suda, M., Tamura, N., Mori, K., Sakuma, Y., Chusho, H., Shiota, K., Tanaka, K. and Nakao, K. (1998) Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/ guanylyl cyclase-B pathway. J. Biol. Chem., 273, 11695–11700.
38. Agoston, H., Khan, S., James, C.G., Gillespie, J.R., Serra, R., Stanton, L.A. and Beier, F. (2007) C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and -independent pathways. BMC Dev. Biol., 7, 18.
39. Miyazawa, T., Ogawa, Y., Chusho, H., Yasoda, A., Tamura, N., Komatsu, Y., Pfeifer, A., Hofmann, F. and Nakao, K. (2002) Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology, 143, 3604–3610.
40. Krejci, P., Masri, B., Fontaine, V., Mekikian, P.B., Weis, M., Prats, H. and Wilcox, W.R. (2005) Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J. Cell. Sci., 118, 5089–5100.
41. Ornitz, D.M., Xu, J., Colvin, J.S., McEwen, D.G., MacArthur, C. A., Coulier, F., Gao, G. and Goldfarb, M. (1996) Receptor specificity of the fibroblast growth factor family. J. Biol. Chem., 271, 15292–15297.
42. Pejchalova, K., Krejci, P. and Wilcox, W.R. (2007) C-natriuretic peptide: an important regulator of cartilage. Mol. Genet. Metab., 92, 210–215.
43. Chrisman, T.D. and Garbers, D.L. (1999) Reciprocal antagonism coordinates C-type natriuretic peptide and mitogen-signaling pathways in fibroblasts. J. Biol. Chem., 274, 4293–4299.
44. Ozasa, A., Komatsu, Y., Yasoda, A., Miura, M., Sakuma, Y., Nakatsuru, Y., Arai, H., Itoh, N. and Nakao, K. (2005) Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells. Bone, 36, 1056–1064.
45. Olney, R.C., Prickett, T.C., Espiner, E.A., Mackenzie, W.G., Duker, A.L., Ditro, C., Zabel, B., Hasegawa, T., Kitoh, H., Aylsworth, A.S. et al. (2015) C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia. J. Clin. Endocrinol. Metab., 100, E355–E359.
46. Hunt, P.J., Richards, A.M., Espiner, E.A., Nicholls, M.G. and Yandle, T.G. (1994) Bioactivity and metabolism of C-type natriuretic peptide in normal man. J. Clin. Endocrinol. Metab., 78, 1428–1435.
47. Lorget, F., Kaci, N., Peng, J., Benoist-Lasselin, C., Mugniery, E., Oppeneer, T., Wendt, D.J., Bell, S.M., Bullens, S., Bunting, S. et al. (2012) Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am. J. Hum. Genet., 91, 1108–1114.
48. BioMarin. (2012) BioMarin Announces Phase 1 Results for BMN-111 for Achondroplasia. Globe Newswire, Novato, CA.
49. Clinical Trials.Gov. (2015) A service of the U.S. National Institutes of Health. A Phase 2 Study of BMN-111 to Evaluate Safety, Tolerability And Efficacy in Children With Achondroplasia (ACH). https://clinicaltrials.gov/ct2/show/NCT02055157?term=achondroplasia&rank=3.
50. BioMarin. (2015) BMN-111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study. lif. Globe Newswire, San Rafael, CA.
51. Laederich, M. and Horton, W.A. (2012) FGFR3 targeting strategies for achondroplasia. Expert. Rev. Mol. Med, 14, e11.
52. Troeberg, L. and Nagase, H. (2012) Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim. Biophys. Acta, 1824, 133–145.
53. Evans, C.H., Ghivizzani, S.C. and Robbins, P.D. (2013) Arthritis gene therapy and its tortuous path into the clinic. Transl. Res., 161, 205–216.
54. Goldring, M.B. and Berenbaum, F. (2015) Emerging targets in osteoarthritis therapy. Curr. Opin. Pharmacol., 22, 51–63.
55. Wu, Z., Asokan, A. and Samulski, R.J. (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther., 14, 316–327.
56. Cucchiarini, M. and Madry, H. (2014) Use of tissue engineering strategies to repair joint tissues in osteoarthritis: viral gene transfer approaches. Curr. Rheumatol. Rep., 16, 449.
57. Evans, C.H. and Huard, J. (2015) Gene therapy approaches to regenerating the musculoskeletal system. Nat. Rev. Rheumatol., 11, 234–242.
58. Kotterman, M.A. and Schaffer, D.V. (2014) Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet., 15, 445–451.
59. Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M.F. and Masurier, C. (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene. Ther., 21, 704–712.
60. Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H. C., Terhorst, C. et al. (2013) Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood, 121, 2224–2233.
61. Zhong, L., Li, B., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R.W., Zolotukhin, I., Warrington, K.H. Jr, Weigel-Van Aken, K.A. et al. (2008) Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. USA, 105, 7827–7832.
62. Munch, R.C., Janicki, H., Volker, I., Rasbach, A., Hallek, M., Buning, H. and Buchholz, C.J. (2013) Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol. Ther., 21, 109–118.
63. Gouze, E., Gouze, J.N., Palmer, G.D., Pilapil, C., Evans, C.H. and Ghivizzani, S.C. (2007) Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases. Mol. Ther., 15, 1114–1120.
64. Goodrich, L.R., Phillips, J.N., McIlwraith, C.W., Foti, S.B., Grieger, J.C., Gray, S.J. and Samulski, R.J. (2013) Optimization of scAAVIL-1ra in vitro and in vivo to deliver high levels of therapeutic protein for treatment of osteoarthritis. Mol. Ther. Nucleic. Acids, 2, e70.
65. Madry, H., Cucchiarini, M., Terwilliger, E.F. and Trippel, S.B. (2003) Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. Hum. Gene. Ther., 14, 393–402.
66. Goodrich, L.R., Choi, V.W., Carbone, B.A., McIlwraith, C.W. and Samulski, R.J. (2009) Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors. Hum. Gene. Ther., 20, 1697–1702.
67. Evans, C.H., Ghivizzani, S.C. and Robbins, P.D. (2011) Getting arthritis gene therapy into the clinic. Nat. Rev. Rheumatol., 7, 244–249.
68. Valverde-Franco, G., Binette, J.S., Li, W., Wang, H., Chai, S., Laflamme, F., Tran-Khanh, N., Quenneville, E., Meijers, T., Poole, A.R. et al. (2006) Defects in articular cartilage metabolism and early arthritis in fibroblast growth factor receptor 3 deficient mice. Hum. Mol. Genet., 15, 1783–1792.
69. van der Kraan, P.M. and van den Berg, W.B. (2012) Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? Osteoarthritis Cartilage, 20, 223–232.